- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02862067
SGLT2 Inhibition in Diabetes and Heart Failure
SGLT2 Inhibition in Diabetic Patients With Heart Failure With Reduced Ejection Fraction
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The investigators hypothesize that Sodium-GLucose coTransporters (SGLT)-2 inhibition will improve cardio-respiratory fitness (CRF) in patients with systolic heart failure.
Participants treated with SGLT2 inhibitor Empagliflozin as standard of care will undergo assessments described below.
The investigators will measure CRF with a validated cardiopulmonary exercise test at baseline and after 4 weeks of treatment received as standard of care, to determine whether SGLT2 inhibition improves cardio-respiratory fitness assessed by changes in peak oxygen consumption (VO2)(mL/kg/min) and minute ventilation (VE)/carbon dioxide production (VCO2) slope, powerful independent clinical predictors of mortality in HF.
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
Virginia
-
Richmond, Virginia, Forenede Stater, 23298
- Virginia Commonwealth University
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Confirmed clinical diagnosis of stable HF (NYHA class II-III) on maximally tolerated HF medical regimen including angiotensin-inhibitors, beta-adrenergic blockers, and loop diuretics
- Reduced left ventricular systolic function (LVEF<50%) documented in the prior 12 months
- Poorly controlled T2DM (HbA1c levels between 6.5% and 10.0%)
- 18 years old and older.
Exclusion Criteria:
- Type I diabetes;
- Type II diabetes with episodes of severe hypoglycemia <50 mg/dl by history, frequent changes in anti-diabetic regimen class in the past 3 months or with a prior episode of diabetic ketoacidosis (any time);
- Open label treatment with SGLT2 inhibitors (within the past month);
- Treatment with thiazolidinedione (within the past month), which may induce volume and sodium retention;
- Chronic Kidney Disease (GFR<45 ml/kg*min);
- Uncontrolled thyroid dysfunction (TSH<0.4>4.5 mcIU/ml);
- Pregnancy or of child-bearing potential;
- Active or recent (within 2 weeks) genital/urinal infection;
- Concomitant conditions or treatment which would affect completion or interpretation of the study including physical inability to walk or run on a treadmill such as decompensated HF (edema, NYHA class IV), significant ischemic heart disease, angina, arterial hypotension (BP systolic <90 mmHg), orthostatic arterial hypotension, arterial hypertension (resting BP systolic >160 mmHg), atrial fibrillation with rapid ventricular response, severe valvular disease, severe chronic obstructive or restrictive pulmonary disease, moderate- severe anemia (Hgb<10 g/dl);
- Abnormal BP or heart rate response, angina or ECG changes (ischemia or arrhy- thmias) occurring during baseline cardio-pulmonary exercise testing;
- Chronic use of oral corticosteroids;
- Inability to give informed consent.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
SGLT2 inhibition effects on cardiorespiratory fitness (CRF).
Tidsramme: 4 weeks
|
To measure the effects of Empagliflozin on cardiorespiratory fitness in patients with type 2 diabetes and heart failure with reduced ejection fraction or systolic heart failure.
The effects on CRF are determined by measuring changes in peak VO2 (mL/kg/min) and the VE/VCO2 slope.
|
4 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Salvatore Carbone, PhD, MS, Virginia Commonwealth University
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- HM20007722
- 16MCPRP31100003 (Andet bevillings-/finansieringsnummer: American Heart Association)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Diabetes mellitus, type 2
-
University Hospital Inselspital, BerneAfsluttetType 2 diabetes mellitusSchweiz
-
India Diabetes Research Foundation & Dr. A. Ramachandran...Afsluttet
-
US Department of Veterans AffairsAmerican Diabetes AssociationAfsluttetType 2 diabetes mellitusForenede Stater
-
Dexa Medica GroupAfsluttetType-2 diabetes mellitusIndonesien
-
AstraZenecaRekruttering
-
Daewoong Pharmaceutical Co. LTD.Ikke rekrutterer endnuT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRekrutteringType 2 diabetes mellitus (T2DM)Kina
-
Newsoara Biopharma Co., Ltd.RekrutteringT2DM (Type 2 Diabetes Mellitus)Kina
-
Shanghai Golden Leaf MedTec Co. LtdAktiv, ikke rekrutterendeType 2 diabetes mellitus (T2DM)Kina
-
SanofiAfsluttet
Kliniske forsøg med Assessment of cardiorespiratory fitness
-
Maastricht UniversityTNO; Netherlands Instititute for Health Services Research; University of...AfsluttetHjertefejl | Diabetes mellitus, type 2 | Kronisk obstruktiv lungesygdom | AstmaHolland
-
Memorial Sloan Kettering Cancer CenterAfsluttetFamilierne eller pårørende til patienter behandlet på MSKCC for ikke-kutane pladecellekarcinomer i | Øvre aerofordøjelseskanalForenede Stater
-
University of MiamiIkke rekrutterer endnu
-
Duke UniversityNational Institute of Mental Health (NIMH)RekrutteringSelvmordForenede Stater
-
University of Wisconsin, MadisonAfsluttetAchilles tendinitisForenede Stater
-
University Rehabilitation Institute, Republic of...University Medical Centre LjubljanaRekrutteringAmyotrofisk lateral skleroseSlovenien
-
Fondazione Policlinico Universitario Agostino Gemelli...RekrutteringMelanom | Nyrekræft | Brystkræft | Mavekræft | Lungekræft | Blærekræft | Hudkræft | HovedhalskræftItalien
-
University of California, San FranciscoAfsluttetFor tidligt arbejde | For tidlig leveringForenede Stater
-
Johns Hopkins UniversityNational Institute on Aging (NIA)AfsluttetDelirium | HoftebrudForenede Stater
-
Seattle Children's HospitalNationwide Children's HospitalRekrutteringSelvmordstanker | Selvmordstrussel | Selvmord og selvskade | SelvmordsforsøgForenede Stater